Navigation Links
Callisto Pharmaceuticals Announces Publication of Research Article,on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

Article Published in Recent Issue of Journal Blood

NEW YORK, April 11, 2007 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the publication of a research article on Atiprimod, Callisto's drug currently in clinical trials in carcinoid cancer and multiple myeloma patients, in the February 2007 issue of Blood, a peer-reviewed scientific journal that publishes original research articles related to hematological malignancies.

The article authored by Dr. Michael Wang and Dr. Qing Yi, from the University of Texas M.D. Anderson Cancer Center, focuses on Atiprimod's ability to inhibit proliferation of mantle cell lymphoma (MCL) cells in vitro and to inhibit growth of MCL tumors in tumor-bearing mice. The animal data demonstrated that Atiprimod significantly inhibited tumor growth in vivo and prolonged survival of tumor-bearing mice. Atiprimod was shown to enhance release of apoptosis-inducing factor (AIF) from cellular mitochondria, and the authors suggest that this is the mechanism of Atiprimod's apoptotic (programmed cellular death) activity.

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients.

The publication appeared in Blood First Edition Paper, prepublished online February 22, 2007 DOI 10.1182/Blood-2006-12-063958 and is titled: "Atiprimod inhibits the growth of mantle cell lymph
'"/>




Page: 1 2 3

Related medicine technology :

1. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/24/2013)... LONDON , May 24, 2013 ... non-invasive administration for systemic delivery of therapeutic agents has ... the inhalation drug delivery showing significant promise. The crucial ... of a delivery device play a major role in ... been made in the development of new formulation techniques ...
(Date:5/23/2013)... 24 de mayo de 2013  Volcano Corporation ... y fabricante de herramientas de precisión para terapia ... de la enfermedad vascular periférica y coronaria, anunció ... Ad enosine V asodilator I ndependent ... la sesión de ensayo clínico hot line late ...
(Date:5/23/2013)... 2013 Nephros, Inc. (OTC Bulletin Board: ... that develops and sells high performance liquid purification ultrafilters, ... In addition, the concurrent temporary reduction in exercise price ... 17, 2013. Nephros estimates that it will ... offering.   A portion of the proceeds will be used ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... VIEW, Calif., Dec. 12, 2011  IRIDEX Corporation (Nasdaq: ... clinical study(1) compiled over 10 years demonstrates the safety ... macular edema (DME) without the retina tissue damage associated ... Centers for Disease Control and Prevention, DME, a swelling ...
... Mylan Inc. (Nasdaq: MYL ) today announced ... Pharma, L.P., Mylan,s fully integrated specialty pharmaceutical business. ... professional experience in strategic product launches, marketing, commercialization, sales ... president and chief executive officer of MiddleBrook Pharmaceuticals. In ...
Cached Medicine Technology:10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema 210-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema 3Mylan Names John Thievon President of Dey Pharma 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 A recent study ... of America dreads the upcoming bathing suit season. Almost 138 ... the weather heats up due to weight issues and a ... mercury rises. PharmaCo Labs recommends that those anxious about ... PhenObestin 37.5 as part of an overall effort to improve ...
(Date:5/24/2013)... myMEDholiday.com, a popular medical tourism portal which ... important medical travel destinations in Asia, has added a ... ensure a safe and successful trip for anyone planning ... tips on cost-savings, how to find the appropriate doctors ... wealth other essential advice. , A top-level marketing representative ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... May 24, 2013 This week is ... and their efforts to provide the best emergency care ... of this week is also to educate the public ... of survival. Citizens are the first link, and a ... proper bystander CPR after a cardiac arrest can triple ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- Patients hospitalized for ... if they,re admitted on Mondays or in the morning, ... of stay are highest among heart failure patients admitted ... researchers, who are scheduled to present their findings Saturday ... Failure Association of the European Society of Cardiology. ...
Breaking Medicine News(10 mins):Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 2Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 3Health News:myMEDholiday.com Introduces International Patient Guide to Assist People Planning Treatment Abroad 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2
... ... expertise in turnarounds and improving hospital profitability joins StatCom in a strategic partnership program that ... ... addition of Tom Brunelle FACHE, MBA, to the StatCom team. Previously Brunelle served as EVP ...
... , , , , , , , , ... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a leading China ... of the acquisition of buildings and land use,rights. The total consideration ... ), which will be financed from working capital. The,initial payment of ...
... ... connectivity combo solution to accelerate time-to-market for handset manufacturers to deliver interoperable sport, ... ... 15, 2010 -- ANT Wireless, a division of Dynastream Innovations Inc. (ANT) and ...
... ... has become the company’s Vice President of Product Services. Among his responsibilities, Randy will ... Notification Network, White Pine’s flagship personal health record solution. , ... (PRWEB) February 14, 2010 -- White ...
... ... Robert Lukasik has joined the company as Vice President of Sales. Separately, Kardea ... , ... 2010 -- Kardea Nutrition ™ LLC announced today that Robert Lukasik has joined the ...
... issue of the Journal of Clinical Sleep Medicine ... (OSA) report a significantly lower frequency of nightmares than ... OSA suppresses the cognitive experience of nightmare recall. ... nightmare recall decreased linearly as sleep apnea severity increased. ...
Cached Medicine News:Health News:Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region 2Health News:Tom Brunelle Joins StatCom as Enterprise VP, Northeast Region 3Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 2Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 3Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 2Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 3Health News:ANT+ and Texas Instruments connect proven ultra low power sensors to smartphones 4Health News:Longtime Quality Assurance Executive Randy Johnson Joins White Pine Systems as Vice President of Product Services 2Health News:Kardea Nutrition Adds V.P. Sales, Extends Distribution Network 2Health News:Severe sleep apnea decreases frequency of nightmare recall 2
... This antimicrobial skin cleanser will not leave ... with frequent washings. With persistent Antimicrobial action, ... of microorganisms, including gram-negative and gram-positive bacteria, ... as a 15 second hand wash. The ...
... Prep Pads prepares the skin for improved ... dry, it leaves a thin film on ... surface and a barrier for natural body ... a dressing or tape. Skin Protectant is ...
... Povidone Iodine Prep Pads ... surface pathogens including bacteria, ... yeast. Povidone Iodine is ... wounds or mucus membranes. ...
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: